™

A comprehensive pharma consulting brief. Custom-built for your commercial question.

The Binding Constraint · The Competitive Map · The Assumption Register · Client Alignment Questions · Every figure sourced.

AXLRx sample brief page — patient funnel AXLRx sample brief page — regulatory table AXLRx sample brief page — KPI dashboard

Pages from a real AXLRx Consulting Intelligence Brief.

★ First brief complimentary. No commitment.

AXLRx lives at axlrx.ai · Report library · Methodology

The AXLRx Advantage

Four dimensions. No trade-offs.

Traditional consulting forces a choice — fast or thorough, affordable or rigorous. AXLRx delivers across all four on every engagement.

01

Faster

A brief in your hands in days. No retainer, no kickoff calls, no status updates — just the output before your next decision.

02

Better

Built to your specific indication, market, and question — not a templatized static report you adapt. Every figure sourced from 50+ live databases and confidence-rated.

03

Smarter

Structured the way consulting is done — binding constraints, assumption registers, scenario models, and live working documents you can field and present.

04

Leaner

Roughly 90% lower cost than a comparable consulting engagement. Consulting-grade depth at a fraction of the price.

Where It Fits

A 3–4 week head start on the groundwork.

AXLRx delivers the 3–4 weeks of primer work — epidemiology, competitive landscape, access architecture — in days, before the strategy engagement begins.

AXLRxThe primer, in daysGroundwork In-HouseInternal team or a firm's primerSyndicated ReportOff-the-shelfGeneric AI ToolChatGPT / Copilot
Time to primerDays3–4 weeks of effortOff-the-shelf, but fixedInstant, but unreliable
Cost~90% lowerWeeks of senior analyst time$10K–$50K per reportFree / low cost
Built to your questionAlways, to your briefYes — built from scratchGeneric, pre-writtenGeneric — no pharma context
Hard-to-source marketsAny market, globallyPossible — slow to sourceMajor markets onlyHallucinated — cannot cite
Working formatsPDF · PPT · Excel · WordYes — hand-builtPDF onlyChat text only
RoleThe primer before strategyThe same primer, done manuallyMarket research, pre-writtenGeneral queries — no depth

AXLRx doesn't replace your strategy team or your consulting firm. It does the 3–4 weeks of groundwork that comes before the strategy — so the real work starts with a head start.

AI engine, with a human expert behind it.45 minutes of senior consulting, free with every brief.

A senior MoatRx consultant walks your team through the findings, pressure-tests the assumptions, and helps turn the intelligence into a decision. How the engine works →

How It Works

Three inputs. A tailored brief. In days.

Define your engagement across three dimensions. AXLRx applies the frameworks a senior consultant would and builds the brief to exactly that scope.

You define your engagement
1Therapeutic Area
OncologyImmunologyRare DiseaseCNSMetabolic+ any indication
2Market
United StatesEU5JapanChinaIndia · GCC+ any market
3Commercial Question
Market EntryCompetitive IntelPatient SizingBD DiligencePayer Access+ any question
→
AXLRx delivers
PDF
Working briefStructured, sourced, decision-ready narrative
XLSX
Live modelEditable patient-flow or sizing model with formulas
PPT
Briefing exhibitsReady-to-present charts and tables
DOC
Discussion guidesKOL and advisory-board-ready
Built to your question. A sizing question returns a model-led brief; a KOL question returns a discussion guide. These are examples, not a fixed pack.
In practice — real engagement questions
Q·01

"What's the addressable patient population for our rare disease asset across the US and EU5, and how does access vary by market?"

Rare Disease · US + EU5 · Patient Sizing
Excel model + brief
Q·02

"We're closing a BD deal in three weeks. What does the competitive landscape look like for this oncology asset in Japan: approved agents, pipeline, and payer access?"

Oncology · Japan · BD Due Diligence
PPT brief + Excel
Q·03

"We're interviewing 15 KOLs across Brazil and India before our advisory board. Build a ready-to-field discussion guide structured by indication and market."

Any TA · Brazil + India · KOL Research
Word discussion guide
Inside Every Brief

Four sections. Shown on the page.

Each section answers a specific commercial question. Below is what those pages look like in an actual AXLRx brief — the section name, what it contains, and the real page alongside it.

01 · The Binding Constraint The variable that decides the whole launch — named, not buried.

Stated as a claim, documented, and challenged. The page your team argues about, and the one that drives every assumption that follows. Every brief opens here.

The Binding Constraint — sample page PDF · p.05 · Strategic Context
02 · The Competitive Map Who's approved, who's winning, where each competitor is vulnerable.

On-market agents, share landscape, and the commercial position behind each brand — structured so you can take a position, not just read a list.

The Competitive Map — regulatory approvals table PDF · p.09–15 · Competitive Map
03 · The Assumption Register Every figure sourced, confidence-rated, and traceable.

Each parameter carries its basis and confidence level. Change one assumption and the linked model updates. Built to survive an internal challenge meeting.

The Assumption Register — sample page PDF · p.06 · Assumption Register
04 · Client Alignment Questions The open questions your team must close before strategy is locked.

Structured by function, ready for your advisory board or internal session. Not a conclusion — a set of decisions your team still needs to make explicit.

Client Alignment Questions — sample page PDF · p.16 · Strategic Questions
Download the full brief to read every section in context Download Alzheimer's CI Brief (PDF) →

Sample shown: Alzheimer's Disease, US. Every AXLRx brief is built to your specific indication, market, and commercial question.

Already Published

More than 300 reports are already written.

Before commissioning one, check whether the answer already exists. More than 300 reports across 21 indications, searchable in the AXLRx library on axlrx.ai.

What It's Grounded In

Grounded in live data and two decades of practice.

20+Years of hands-on pharma commercial consulting, built into the engine
100+Consulting engagements across the commercial value chain
200+Real cases and commercial playbooks built into the methodology

Drawing on 50+ live, cited data sources

Peer-reviewed literaturePubMed · MEDLINE · bioRxiv · Consensus
Clinical trialsClinicalTrials.gov · endpoints and investigators
Regulatory and approvalsFDA (OpenFDA) · EMA · DrugBank
Disease burden and epidemiologyWHO (GHO) · ICD-10 · Open Targets
Pipeline and competitiveAdisInsight · pipeline, deals and competitors
Payer, HTA and financialCMS Coverage · HTA bodies · SEC EDGAR · Quartr

The team behind AXLRx, in the press

Built For

Teams that need intelligence at pace.

Consulting-grade intelligence on your timeline, not a retainer schedule.

FAQ

Questions teams ask before the first brief.

What is AXLRx?

AXLRx is MoatRx's pharma commercial intelligence service: it builds a consulting-grade brief for your specific therapy area, market and commercial question, in days. Each brief opens with the binding constraint, maps the competition, and sources every figure in an assumption register.

How long does an AXLRx brief take?

A brief is delivered in days. There is no retainer, no kickoff call and no status updates: you define the therapy area, market and question, and the output arrives before your next decision.

What do I receive?

You receive the formats your question needs: a sourced PDF brief, an editable Excel model, ready-to-present PowerPoint exhibits, or a Word discussion guide for KOL interviews and advisory boards. A sizing question returns a model-led brief; a KOL question returns a discussion guide.

Which therapy areas and markets does AXLRx cover?

Any therapy area and any market. Examples include oncology, immunology, rare disease, CNS and metabolic, across the United States, EU5, Japan, China, India, the Gulf and harder-to-source markets.

How is AXLRx different from ChatGPT or another generic AI tool?

Every figure in an AXLRx brief is drawn from cited live sources such as PubMed, ClinicalTrials.gov, FDA, EMA and WHO, and is confidence-rated; generic AI tools give uncited chat text with no pharma context. Each brief also comes with 45 minutes with a senior MoatRx consultant who pressure-tests the findings.

Does AXLRx replace our consulting firm or strategy team?

No. AXLRx does the 3–4 weeks of primer groundwork that comes before a strategy engagement (epidemiology, competitive landscape, access architecture), so the strategy work starts with a head start.

Can I try it before committing?

Yes. Your first brief is complimentary, with no commitment: pick a real question your team is working on now.

Are there reports I can read today?

Yes. More than 300 AXLRx reports across 21 indications are already published and searchable in the AXLRx library at axlrx.ai/library.

Bring us your hardest commercial question. On us.

Pick a real engagement your team is working on now. First brief complimentary. Any TA, any market, any question.